Skinny Blend (Cagrilinitide 5mg +Sema 5mg)

Sold by case = 10 vials

Skinny Blend (Cagrilinitide 5mg + Semaglutide 5mg)

For Research Use Only. Not for Human or Veterinary Consumption.

This peptide combination pairs Cagrilinitide, a synthetic amylin analog, with Semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist. Researchers use this dual-peptide system to investigate synergistic effects on appetite regulation, gastric motility, and metabolic pathways in laboratory models. The combination supports studies into energy balance, glucose homeostasis, and gastrointestinal signaling mechanisms.

This product is intended strictly for qualified laboratory research and is not approved for therapeutic, diagnostic, or human use.

Mechanism of Action

Semaglutide:

• Activates GLP-1 receptors, studied for effects on insulin secretion, glucagon suppression, and appetite regulation in experimental models.

• Investigated for delaying gastric emptying and its impact on satiety signaling pathways.

• Explored for roles in glycemic control and modulation of lipid metabolism in research settings.

Cagrilintide:

• Mimics amylin hormone activity, studied for regulation of appetite and gastric motility in laboratory models.

• Enhances satiety signaling through central nervous system pathways in experimental systems.

• Supports GLP-1 receptor activation effects by slowing gastric emptying and reducing nutrient intake.

Synergistic Interaction:

• Combination enables researchers to examine additive effects on appetite suppression, metabolic regulation, and energy balance.

• Used to model integrated hormonal pathways influencing glucose homeostasis and fat metabolism in controlled studies.